| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4166859 | The Journal of Pediatrics | 2011 | 7 Pages |
Abstract
The off-label use of rFVIIa in hospitalized children is increasing rapidly despite the absence of adequate clinical trials demonstrating safety and efficacy. Thrombotic events are common and mortality is high among patients receiving off-label rFVIIa. Further studies are warranted to determine whether these adverse events are attributable to rFVIIa.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Char M. MD, Yuan-Shung MS, Kevin PhD, Leslie J. MD, MSCE, Samir S. MD, MSCE,